Multihance (Gadobenate Dimeglumine)

Gadobenate dimeglumine, the active ingredient in Multihance, is a gadolinium-based contrast agent presented as a 0.5 mmol/mL injection solution for intravenous use. It enhances magnetic resonance imaging of the brain, spinal cord, liver and cardiovascular system in patients undergoing diagnostic scans.

GNH USA supplies Multihance as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Multihance (gadobenate dimeglumine) is a gadolinium‑based contrast agent used in magnetic resonance imaging to improve visualization of specific anatomical regions.

- MRI of brain and spinal cord: provides enhanced delineation of lesions and normal structures. - MRI of liver: improves detection and characterization of focal liver lesions. - MRI of cardiovascular system: enhances visualization of cardiac chambers, vessels and myocardial tissue.

Multihance may cause a range of adverse reactions following intravenous administration.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Headache: transient discomfort. - Injection site discomfort: pain or warmth at the site. - Metallic taste: brief sensation in the mouth.

Serious or Rare Side Effects: - Allergic reactions: including anaphylaxis. - Nephrogenic systemic fibrosis: in patients with severe renal impairment. - Severe hypotension: sudden drop in blood pressure. - Pulmonary edema: fluid accumulation in the lungs.

Prior to using Multihance, several safety considerations should be observed.

- Assess renal function: evaluate eGFR to mitigate NSF risk. - Pregnancy and lactation: use only if benefits outweigh potential risks. - History of allergic reactions: avoid in patients with known hypersensitivity. - Severe hepatic impairment: consider limited hepatic uptake. - Pediatric use: restrict to cases where diagnostic benefit justifies exposure. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Multihance may interact with other agents that affect renal function or cumulative gadolinium exposure.

Major Interactions (Avoid): - Concurrent high‑dose gadolinium agents: increase toxicity risk. - Use with other linear gadolinium agents: elevate NSF risk.

Moderate Interactions (Monitor Closely): - Loop diuretics: may alter renal clearance. - ACE inhibitors: potential impact on renal function. - NSAIDs: can affect kidney performance. - Calcium channel blockers: minor influence on hemodynamics.